Mylan's EpiPen price increases have received a significant amount of press coverage recently, Wells Fargo analyst David Maris tells investors in a research note. He points out that Senator Bernie Sanders tweeted yesterday to his 2.4M followers: "There's no reason an EpiPen, which costs Mylan just a few dollars to make, should cost families more than $600." Maris believes that while price EpiPen raises can benefit near-term earnings, Mylan is unlikely to benefit in the long run from this type of scrutiny. The analyst has a Market Perform rating on shares of Mylan with a $43-$45 price target range.